Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Novartis ends ALS program after phase 2 flop, adding to R&D woes
(19h)
Novartis pays Sironax $125M to acquire platform for crossing the blood-brain barrier
(21h)
Sling reels in $123M series C to fund oral Tepezza rival through phase 3 trial
(1d)
FDA launches pilot program to speed up sluggish phase 1 trials
(1d)
Connect's Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope
(1d)
BioPharma Dive
Novartis to pay $125M for blood-brain barrier crossing platform
(13h)
Novo looks to Anthropic’s AI models to ‘supercharge’ drug development
(18h)
Sling banks $123M for an experimental thyroid eye disease pill
(18h)
Skyhawk racks up more support for Huntington’s drug
(20h)
FDA clears first generic radioligand drug; Sionna turns to layoffs
(1d)
Endpoints News
Drugmakers cooperate with House probe of China trial sites
(15h)
FDA faces questions on 'America First' provisions in latest user fee agreement
(16h)
Gilead reaches HIV PrEP agreements; Hong Kong investigates Cloudbreak IPO
(18h)
Researchers implant human neurons in mice brains to study disease
(18h)
Novo signs Anthropic deal to test Claude Science in RD
(19h)
BioSpace
Biopharma hiring hotspots: States, disciplines where demand is highest
(2h)
Trending: Top biopharma disciplines with jobs live now
(2h)
FDA warning letter accuses Bausch & Lomb of lacking commitment to remediation
(19h)
Deep dive: Psychedelics back on FDA’s doorstep
(19h)
Novartis halts TREM2 targeting ALS program in 4th trial stumble in a month
(20h)
STAT News
The FDA’s rebuilding effort is running into a new challenge
(1h)
What happened to oppositional defiant disorder?
(1h)
England to cover AstraZeneca breast cancer drug, a result of U.K.-U.S. drug pricing deal
(2h)
New lawsuit argues NIH violated First Amendment rights of grant applicants
(9h)
GOP aims to change Medicare adviser’s math to help out private insurers
(13h)
BioPharma Trend
The Bigger Point Beyond Insilico's Aging Research Milestone
(1w)
The Measurement Challenge in Longevity: Can Aging Biomarkers and Clocks Close the Gap?
(1w)
What the New AI Model Releases by Anthropic and OpenAI Change for Life Sciences
(2w)
Into the Dark: Finding Novel Drug Targets Within the Depths of Our Proteome
(2w)
Beyond the Code: How DNA Nanotechnology is Moving from Molecular Origami to Programmable Biotech Platforms
(4w)
Drug Channels
Preorder DCI’s New 2026-27 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors
(2d)
Informa Connect’s Pharma/Biotech GTN Summit
(3d)
Drug Channels Leadership Forum 2027: Antonio Ciaccia to Serve as Moderator
(1w)
BlinkRx Insights: Beyond the Hub - Rethinking the Prescription Journey
(2w)
The Private Label Biosimilar Paradox in Medicare Part D
(2w)
European Biotechnology Magazine
SLAS Journals Spotlight AI in Drug Discovery
(2h)
Sensorion files confidentially for potential U.S. IPO
(18h)
The Strüngmann legacy, passed on
(1d)
3PBIOVIAN Appoints Ponchi Kantt-Neaz as Global Executive Business Director
(1d)
ResoTher heart data clear acquisition hurdle, set up 200-patient trial
(1d)
Drug Hunter
enpatoran (M5049)
(19h)
pociredir
(1d)
How Pyridazinones Mimic Amides, Phenols, and Nicotinamides
(2d)
Lessons from Recently Approved Oral Small Molecules: Dose Regimens, PK, and Safety
(5d)
MK-1088
(5d)
Labiotech.EU
Oncology biotech news: key moves to watch in September 2026
(21h)
New non-opioid pain medication: How is the biotech industry fighting pain after the opioid crisis?
(1d)
BIOSPAIN 2026: Spain’s flagship biotech event is going annual
(2d)
Beyond Ozempic: the GLP-1 landscape in 2026
(2d)
NLS Days 2026: what’s dealmaking like in the Nordics?
(5d)
Bio IT World
A 1970s Lipid-Lowering Compound May Offer a New Approach to Obesity
(1d)
Lehigh Team Uses Digital Twin of Gut-Brain Axis to Advance Neurostimulation Therapies
(2d)
What It Takes to Make Generative AI Fit for GMP
(6d)
Ultima, NVIDIA, Google Partner on Pangenome-Aware Whole Genome Sequencing
(1w)
Clearing the Bench-To-Bedside Hurdle: Why Translational Medicine Needs to Start Earlier
(2w)
GEN News
Brain Protein in Mice Offers Insights Into Brain Development and ADHD
(13h)
Prophylactic Phage Therapy Protects Mice Against Oral Salmonella Infection
(14h)
Cellares and GenomeFrontier Therapeutics Partner to Advance Automated Manufacturing of GF-CART01
(15h)
Prime Assembly Expands Genome Editing with Precise, Large-Scale DNA Integration
(15h)
Red Light Supercharges Anti-Obesity Drug Precursor
(17h)
Cure Today
Gentle Exercises to Keep You Moving During Cancer Treatment feat. Jennifer Tipton
(11h)
Imfinzi Plus Chemotherapy Raises 3-Year Survival to 69% in Gastric Cancer
(16h)
Childhood Leukemia Survivor Shares Her Experience With ALL, Relapse and CAR-T
(1d)
Echoes of the Battle: Navigating Post Cancer Trauma
(1d)
Enhertu in HER2-Mutant Lung Cancer: The First Year, Side Effects and Sequencing
(1d)
Contract Pharma
Gilead Partners With Pan American Health Organization on Lenacapavir Access for Latin America, Caribbean
(14h)
Thermo Fisher Launches SuperScript V Reverse Transcriptase
(14h)
Lilly TuneLab, Twist Bioscience Partner on Antibody Drug Discovery - contractpharma.com
(17h)
Piramal Pharma Plans Solar Power Plant in UK
(18h)
Hovione Doubles US Spray-Drying Capacity With Opening of New NJ Facility
(18h)
Pharma Times
Jemperli accepted for priority review by US FDA
(2w)
Carterra supports AI‑designed protein study with HT-SPR platforms
(2w)
Erasca secures FDA fast track for eras‑0015 in pancreatic cancer
(3w)
Avulux gains FDA authorisation for migraine light‑sensitivity lens
(3w)
Leqembi Iqlik launches in US for early Alzheimer’s
(3w)
Medcity News
Novartis Gains a Way to Get Drugs Into the Brain, Buying Sironax Tech for $125M
(15h)
As MA Denial Rates Rise, Hospitals Are Betting on Traditional Medicare Instead
(17h)
AI Isn’t a Therapist, but Many Teens Are Treating It Like One
(19h)
Hospital Margins Fell This Summer Amid Outpatient Slowdown, Data Shows
(1d)
Thatch Secures $108M, Reaches $1B Valuation
(1d)
Chemical & Engineering News
Why the Reflecting Pool coating peeled and blistered
(12h)
What did a group of Priestly Medalists have to say about the future of chemistry?
(18h)
Comment: Building stronger local sections for the future
(20h)
Editorial: We can have both prosperity and sustainability
(23h)
Groups cite huge health costs from EPA’s power plant GHG rollback, vow to sue
(1d)
The Pharma Letter
Boehringer halts Phase III kidney trial of vicadrostat/Jardiance combination
(48m)
ICER releases evidence report on treatment for Parkinson’s disease
(16h)
Vivan and Ad Atomica pair tumor genotype data with AI drug design
(16h)
Sling Therapeutics announces $123M financing
(19h)
Top-20 Novartis shareholder demands board shake-up after back-to-back trial failures
(19h)
Targeted Oncology
After the First ADC Fails, HR-Positive Breast Cancer Sequencing Runs on Judgment, Not Trial Data
(12h)
Tam-Peli Extends Survival in Relapsed Small Cell Lung Cancer
(15h)
FDA Accepts Bezuclastinib NDA for Advanced Systemic Mastocytosis
(17h)
Sacituzumab Govitecan Combo Misses PFS End Point in PD-L1–High NSCLC
(18h)
Rib-Sparing Approach Lowers Post Thoracotomy Pain
(19h)
MedWatch
Lundbeck Foundation secures more votes through share exchange
(25m)
New CEO appointment eases strategy concerns at Bavarian Nordic, Jefferies says
(26m)
Bavarian Nordic names new CEO
(46m)
Ascendis faces financial setback after patent dispute – Yet the CEO sees the outcome as a victory
(3h)
WSA chair supports call for new CFO to have IPO experience: Nevertheless says it's not decisive
(19h)
In The Pipeline
The ACS Redesign
(1d)
Not The Glue They Thought It Was
(2d)
The State of AI Antibody Design
(5d)
Phosphorylate and Spare Not
(6d)
More Impossible-to-Ignore Vaccine Effects
(1w)
Pharmaphorum
NICE finally backs Enhertu for HER2-low breast cancer
(33m)
Novo taps Anthropic's Claude AI for drug discovery
(1h)
Wales takes UK lead on needle-free anaphylaxis prevention
(17h)
Legend Biotech names ex-Novartis exec as CEO
(20h)
TikTok parent ByteDance raises cash for drug AI spinout Anew
(21h)
Drug Discovery Weekly
Wegovy pill could help patients lose 17% body weight
(3mo)
How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease
(3mo)
Webinar: Learn how to accelerate the early stages of drug discovery
(3mo)
Therapy enables 89% survival rate in myeloma patients
(3mo)
Ulcerative colitis treatment shows best-in-class potential
(3mo)
HIT Consultant
M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care
(15h)
Biohacking’s Gender Problem: Why Women’s Health Protocols Require Dedicated Research and Clinical Variables
(18h)
R1 Unveils Phare Utilization Management on Phare OS to Eliminate Medical Necessity Denials
(18h)
M&A: MRO Acquires Vyne Medical to Expand Intelligent Healthcare Intake Automation
(20h)
FDA Awards Cognita Imaging $1.29M to Validate LLM-as-a-Jury Evaluation Across 1 Million Radiology Reports
(20h)
Insights: Pink Sheet
No Letup In Aging Japan’s Rising Health, Drug Costs
(6h)
OTC Industry Makes First PDUFA Appearance After Months of Behind-the-Scenes Negotiations
(9h)
Big Pharma CEOs Bullish On US Policy Environment Heading Into Midterm Elections
(11h)
PDUFA VIII’s ‘America First’ Fee Incentives Could Be Gamed, Stakeholders Warn US FDA
(12h)
FDA Nominee Heidi Overton Could Appear Before Senate Panel As Soon As Sept. 24
(13h)
BioXconomy
FDA to boost overseas trial site inspections amid concerns about regulatory oversight capacity
(12h)
RegCell banks $66m to advance Nobel-winning immune tolerance platform
(17h)
Japan’s hybrid DCT approach shaped by unique regulations, healthcare system, and geography
(18h)
GSK bets up to $750m on Chimagen's multiple myeloma treatment
(23h)
Shennon lands $12m and new CEO to drive immunotherapy pipeline forward
(1d)
BioCentury
Academic deals stay close to home
(9h)
Science Spotlight: A macrophage-recruiting bispecific, plus new tactics against TCR-T escape and tumor stroma
(12h)
Sleep deals cluster in narcolepsy and sleep apnea
(13h)
FDA fills in blanks on expedited IND pilot
(1d)
Novartis commercial leader Ingrid Zhang named Legend CEO
(1d)
SCRIP
Roivant’s Push To Become More Than A Pipeline Story
(45m)
Amgen Confident In Cardiometabolic Pipeline After Novartis’s Negative Lp(a) Readout
(11h)
Novartis’s VHB937 Latest To Join ALS Clinical Development Graveyard
(12h)
Big Pharma CEOs Outline US Policy Goals Heading Into Midterm Elections
(13h)
Sling Raises $123m As It Takes Oral TED Drug Contender Into Phase III
(16h)